Deutsche Bank Cuts Sanofi Target To EUR 95 After MOBILIZE Trial Halt

Deutsche Bank has adjusted its 12-month price target for Sanofi (SASY.PA), lowering it to EUR 95 from the previous EUR 100. This downward revision reflects a recalibration of the company’s clinical pipeline prospects following the official announcement that Sanofi is stopping its Phase 3 MOBILIZE study.

The trial, which was investigating the efficacy of riliprubart in treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), was halted after interim data failed to meet the necessary benchmarks for success. The discontinuation of this late-stage asset is a significant development, as it removes a potential growth driver from Sanofi’s mid-term portfolio and necessitates a renewed focus on other areas of the company’s extensive research pipeline.

Clinical Setback Impacting Valuation

The decision to discontinue the MOBILIZE trial was communicated to investors earlier in June 2026. According to official company statements, the internal analysis indicated that the drug candidate would not achieve the primary endpoints required to justify further investment in the current study format.

While Sanofi remains a leader in the global pharmaceutical landscape, the setback underscores the inherent risks in late-stage drug development. Deutsche Bank’s analysts, while adjusting the price target, continue to monitor Sanofi’s broader performance. The firm maintains a disciplined approach to capital allocation, and market observers are looking for how the company will pivot its research efforts in the wake of the MOBILIZE trial outcome.

Broad Portfolio Performance

Despite the trial halt, Sanofi’s underlying business remains anchored by its strong position in immunology, vaccines, and its ongoing digital transformation initiatives. Recently, the company has made headlines for deploying AI-driven "Concierge for Field" agents on the Snowflake platform to optimize global sales force efficiency.

Furthermore, Sanofi reported positive Phase 2 results for its investigational drug efdoralprin alfa earlier this year, which demonstrated superiority over standard-of-care therapies in treating rare diseases. These developments provide a counter-narrative to the MOBILIZE trial discontinuation, suggesting that while specific clinical programs may face hurdles, the overall research engine remains productive.

Official Sources and Regulatory Context

Official information regarding the trial status was confirmed by Sanofi in its corporate communications issued to the Euronext Paris exchange. Analysts at Deutsche Bank have integrated this data into their updated valuation models. For comprehensive financial details and clinical trial updates, investors typically refer to the Sanofi Investor Relations portal and official filings submitted to the Autorité des marchés financiers (AMF).

Why It Matters

For investors, the lowering of the price target reflects a conservative shift in valuation models that account for the loss of anticipated revenue from riliprubart. For patients and the healthcare sector, the discontinuation of the MOBILIZE trial means that clinical efforts must be re-evaluated to find more effective treatments for CIDP. This event serves as a reminder of the volatility associated with pharmaceutical stock valuations, which are often heavily dependent on the success of individual clinical "pipeline" assets.

Key Facts at a Glance

• Revised Price Target: EUR 95 (previously EUR 100).

• Key Catalyst: Discontinuation of the Phase 3 MOBILIZE study.

• Study Focus: Investigational drug riliprubart for CIDP.

• Broader Strategy: Continued investment in AI-driven sales and rare disease therapies like efdoralprin alfa.

FAQ

Why did Deutsche Bank lower Sanofi's price target?

The target was lowered to EUR 95 from EUR 100 primarily due to the discontinuation of the Phase 3 MOBILIZE study, which reduces the expected future value of the company’s late-stage pipeline.

Does this mean Sanofi is struggling?

Not necessarily. While the MOBILIZE trial was a setback, the company maintains other successful programs, such as positive results for efdoralprin alfa, and continues to innovate in areas like AI-integrated sales systems.

Where can I find official information on Sanofi’s clinical trials?

Official clinical trial updates and corporate announcements are regularly published on the Sanofi Investor Relations website.

What is the current outlook for Sanofi stock?

Market outlook varies among analysts, but the consensus continues to focus on the company's ability to balance its diverse portfolio of immunology and rare disease assets against the risks inherent in clinical development.

Source: Sanofi Corporate Press Releases, Deutsche Bank Research, Autorité des marchés financiers (AMF).